ABSTRACT. Inhaled nitric oxide has been reported to act as a specific pulmonary vasodilator. We used the newborn piglet to create acute hypoxic pulmonary hypertension and examined the effect of inhaled nitric oxide in this model. Six newborn piglets were instrumented in order to measure cardiac index, pulmonary arterial pressure, and systemic arterial pressure. Pulmonary hypertension was induced by reducing the fraction of inspired oxygen to 0.12 to 0.14. With hypoxia (arterial oxygen saturation between 35 and 45%), pulmonary arterial pressure increased by 48% ( p < 0.01), pulmonary vascular resistance increased by 74% ( p < 0.01), and both systemic arterial pressure and systemic vascular resistance decreased by 38 and 31% respectively There is now good evidence that at a cellular level vascular muscle tone is regulated in large measure by NO or an NOrelated compound, which is thought to be identical to the previously described EDRF (1-4). Nitroso-containing vasodilators, such as nitroprusside, are thought to act through liberating NO in tissue (5, 6). NO is synthesized by the vascular endothelium from L-arginine (7, 8), and acts through the stimulation of guanylate cyclase, leading to the production of cyclic GMP (9. 10). The mechanism by which cyclic GMP relaxes vascular smooth muscle is not clear, but probably involves inhibition of activation-induced elevation in cytosolic calcium concentration
< 0.01), and both systemic arterial pressure and systemic vascular resistance decreased by 38 and 31% respectively ( p < 0.01). The animals were then giving varying concentrations of inhaled nitric oxide between 5 and 80 parts per million in random order. All concentrations of nitric oxide were associated with a rapid decrease in pulmonary arterial pressure and pulmonary vascular resistance (p < 0.001). Cardiac index increased ( p < 0.001) and systemic vascular resistance significantly decreased ( p = 0.01) with all doses of inhaled nitric oxide. The ratio of pulmonary to systemic vascular resistance decreased with all levels of inhaled nitric oxide (p < 0.001). For all of the above observations there was no significant difference noted between the varying doses of nitric oxide. The time course of the pulmonary arterial pressure response to nitric oxide was approximately twice as fast as that seen with the inhalation of 100% oxygen (10, 50 , 90% responses of 4.1, 8.8 , 88.6 versus 6.7, 51.9, 197 There is now good evidence that at a cellular level vascular muscle tone is regulated in large measure by NO or an NOrelated compound, which is thought to be identical to the previously described EDRF (1-4). Nitroso-containing vasodilators, such as nitroprusside, are thought to act through liberating NO in tissue (5, 6) . NO is synthesized by the vascular endothelium from L-arginine (7, 8) , and acts through the stimulation of guanylate cyclase, leading to the production of cyclic GMP (9.
10). The mechanism by which cyclic GMP relaxes vascular smooth muscle is not clear, but probably involves inhibition of activation-induced elevation in cytosolic calcium concentration Using a pulmonary hypertension model induced by the infusion of a thromboxane analog, heparin-protamine reaction, or hypoxia, Frostell, Fratacci and co-worker5 ( 12, 1 3) demonstrated reversal of pulmonary vasoconstriction using 40 to 80 ppm of inhaled NO without significant effect on the systemic circulation in 25-to 35-kg mature lambs. Similar results using pulmonary vasoconstriction produced by hypoxia with or without respiratory acidosis were obtained by Roberts et al. (14) who also demonstrated elevated plasma cyclic GMP levels after NO inhalation in a newborn lamb model. Kinsella et al. (1 5) evaluated the effects of NO in mechanically ventilated ovine fetuses maintained at intrauterine arterial oxygen levels. NO (5-20 ppm) produced an increase in pulmonary artery blood flow, an effect that was equal to the response seen when the Fioz was increased to 1 .O. In all of these studies there was no effect on the systemic circulation, specifically on SVR, and in two studies (14, 15) an increase in left-to-right shunting across the ductus occurred during NO inhalation, demonstrating that inhaled NO is a potent selective pulmonary vasodilator in these models.
The aims of the current study were to investigate the feasibility of administering NO to a neonatal model, i.e. the 1-to 2-d-old piglet, and to evaluate the dose response characteristics and the time course of the effect of NO on hypoxic pulmonary vasoconstriction.
MATERIALS AND METHODS
NO Administration. NO in nitrogen in a concentration of approximately 800 ppm was obtained (Canadian Liquid Air, Montreal, Quebec). This source was certified to be f 2% of the analyzed component (NO), and to contain <5 ppm NOz. Singlestage stainless steel diffusion-free regulators were utilized and each regulator was flushed to ensure that any air or other byproducts such as NOz were removed. This source gas was connected at a regulated pressure of 50 psi using Teflon tubing to the input port of a Matheson #603 flowmeter (Matheson Gas Products Canada Inc., Edmonton, Alberta), and then injected at the desired flow rate into the inspiratory line of a time-cycled pressure-limited neonatal ventilator (Sechrist IV 100B, Sechrist Industries, Anaheim, CA), having a continuous gas flow of 12 Llmin. The resulting gas mixture was sampled downstream of the injection site and analyzed for NO, NO2 and total oxides of nitrogen using a chemiluminescence analyzer (model 42H, Thermo Environmental Instruments Inc., Franklin, MA). The concentration of NO2 was also checked using indicator tubes (Draeger tube CH30001, Draeger Canada Ltd., Mississauga, ON). Exhaled gas and exhaust from the analyzer was scavenged. The blender of the ventilator was connected to oxygen and nitrogen to enable the delivery of a hypoxic gas mixture.
Animal Preparation. Mixed strain newborn piglets were obtained on the first or second day of life. Initial anesthetic induction was by inhaled halothane 5%, reduced to 2% when the animal was stable. A bolus of 20 pg/kg of fentanyl and 0.2 mg/ kg of acepromazine was given after tracheostomy surgery and insertion of a jugular venous line, followed by a continuous fentanyl infusion of 10 pg/kg/h. An incision in the right side of the neck allowed the insertion of a catheter through the external jugular vein into the right atrium, through which maintenance i.v. fluid of 30 mL/kg/h of 5% glucose was infused. A catheter was placed in the carotid artery for measurement of SAP. After the tracheostomy, halothane was discontinued, assisted ventilation was started, and paralysis was obtained using pancuronium bromide (0.1 mg/kg) every 45 min. Further bolus doses of fentanyl (5-10 pg/kg) were administered as necessary. Through a left thoracotomy, a 6-or 8-mm ultrasound flow probe (Transonic~ Inc., Rochester, NY) was placed around the pulmonary artery for measurement of cardiac output and 4-to 6-mm probe was also placed around the ductus arteriosus. A 22-gauge catheter was inserted into the root of the pulmonary artery through a purse string suture for the continuous measurement of PAP. The systemic and pulmonary catheters were connected to pressure transducers and together with the ECG signal, displayed on a neonatal monitor (model 78833B, Hewlett Packard, Waltham, MA). Saq was measured using a transcutaneous pulse oximeter (N200, Nellcor Inc., Hayward, CA). A continuous infusion of bicarbonate (1 5 mEq1100 mL of i.v. fluid) was given to prevent severe acidosis during the periods of hypoxia.
Procedure. After this instrumentation, the animal was allowed to rest for 20 min to ensure stability, which was defined as less than 5% variation in heart rate, SAP, and PAP over a 5-min period, and thereafter hypoxia was induced by reduction of the inspired oxygen concentration to 10 to 14% to produce a target Sao2 of 35 to 45%. After the induction of hypoxia, a stable hypoxic baseline was obtained (2 min). An arterial blood specimen was obtained for the measurement of blood gases and methemoglobin.
NO was then administered according to a computer-generated random sequence in doses of 5, 10, 20, 30, 40, 60, or 80 ppm, maintaining the Fio2 at the same level. Administration of NO of greater than 20 to 30 ppm was associated with a slightly lower Fio2, which was then readjusted to baseline.
Measurements were obtained at each dose when there were no further changes in PAP, Sao2, SAP, or cardiac output, and the signals were recorded for 1 min. An arterial blood specimen was drawn, the NO was discontinued, and a subsequent hypoxic baseline recorded. This procedure was repeated until all of the doses of NO had been administered. If the animal experienced significant hypotension (systolic arterial pressure decreasing to less than 60% of the hypoxic baseline) the hypoxia was terminated and the animal was allowed to recover before reintroducing hypoxia.
Data Acquisition. The physiologic parameters of interest were acquired through a personal computer (Dell 486133, Dell Computer Corporation, Richmond Hill, ON) using an analog-todigital converter (DT2801, Data Translation Inc., Marlborough, MA). Software for acquisition analyses were written using Asyst Scientific Software System (Macmillan Software Co., New York, NY). With this software, continuous acquisition of the measured parameters was performed for a 2-min period at baseline, and a 1-min period after stability during each hypoxic NO exposure.
The computer-generated averages of the measured parameters were then utilized for subsequent analyses. The time response of the changes in PAP were similarly analyzed using the average values for each I s for the PAP to determine the time response of the change in the PAP compared to baseline. All signals were acquired at 24 Hz. In order to compensate for the sampling delay time of the analyzer which was approximately 5 s, initiation of the response was considered to be 5 s before the initial indication that the appropriate dose of NO had been measured by the analyzer.
Cardiac output was determined from the measurements of the calibrated ultrasonic flow probe. Cardiac index was calculated as cardiac output divided by the animal's weight in kilograms. SVR was calculated as mean SAP divided by cardiac index. PVR was calculated as the mean PAP divided by cardiac index.
Statistical Methods. The comparison of changes in the PAP with different doses of NO was evaluated using a randomized block design analysis of variance comparing both the dose of NO and the individual animal's responses. If a significant difference was determined, the intergroup differences were determined using the Student Newman Keuls method with a p value of <0.05 being considered significant. This protocol received the approval of the University of Alberta Animal Welfare Committee and all procedures performed during the experiment were within the guidelines established by Health and Welfare Canada for care of animals (1 6).
RESULTS
Six 1-to 2-d-old piglets were studied. The weight at the time of the study ranged from 1.2 to 1.8 kg with an average weight of 1.36 kg. The mean normoxic and hypoxic baseline cardiovascular parameters are shown in Table 1 . With hypoxia, there was a significant increase in PAP and PVR (48 and 74%; p < 0.01), a significant decrease in SAP and SVR (38 and 3 1 % respectively, p < 0.01), and no significant change in cardiac index. The absolute changes in SAP and PAP are shown in Figure I . The changes in PVR and SVR are shown in Figure 2 .
With the administration of NO there was a significant decrease in PAP at all doses of NO ( p < 0.001; Fig. 1 ). Although the maximal decrement appeared to be with 80 ppm, there were no significant differences in PAP between any of the NO doses other than with comparisons of each dose to baseline. SAP did not significantly change with NO. The PVR, which increased markedly with hypoxia, decreased with all doses of NO ( p < 0.001) and there were no significant differences between the various doses of NO. The cardiac index increased at all NO doses ( p < 0.001) with no differences observed between the varying NO doses, and as a result, SVR decreased with each dose of NO ( p = 0.01). The ratio of PVR divided by SVR (Fig. 3) decreased significantly with each dose of NO ( p < 0.001), but as for the other observations, there were no significant differences between the varying doses of NO. Flow through the ductus arteriosus was extremely low, so it was not possible to draw any conclusions regarding ductal shunting in this model. The time course of the response of PAP to NO compared to 100% oxygen is shown in Figure 4 . Two-way analysis of variance of these time responses showed a significant difference between the responses to oxygen and NO overall ( p < 0.01), but no gestational age, demonstrated that the response to 80 pprn inhaled NO was significantly greater than that seen at 20 ppm. Although there does appear to be a consistent maximal effect with 80 pprn in the newborn piglet, we found no statistical advantage in going beyond 5 pprn in terms of the absolute decrease in PAP and reduction in PVR. The PVRISVR ratio was also significantly reduced from baseline with each dose of NO, the maximum decrease being seen at 80 ppm, but again there were no significant differences between the varying doses of NO. It may be that there are species differences in the dose response to inhaled NO, or more likely, it may be that our failure to demonstrate a significant incremental dose response is due to the small number of animals studied.
Comparison of the time course of the PAP response to NO with that to 100% oxygen demonstrates a significantly faster response to NO. With oxygen, 90% of the total response occurred on average after 197 s, compared with 89 s for NO. It seems likely that the more rapid time course of pulmonary vasodilation observed in our piglet model with the inhalation of NO when compared with inhalation of oxygen, is due to the direct effect of NO diffusion to the smooth muscle cells of the small pulmonary arteries, whereas inhaled oxygen acts through the generation of endogenous EDRF in the endothelium, which then has to diffuse to the muscle cell.
This is the first study of inhaled NO using the newborn piglet model, which raises the question of the suitability of this model. Zellers and Vanhoutte (27) have demonstrated that rings of piglet pulmonary arteries demonstrate endothelium-dependent relaxation and that artery rings from which the endothelium had been removed respond to NO. In addition, the oxygen dissociation curves of human and porcine blood are similar in shape, although the porcine curve lies to the right of the human, so that the newborn piglet would seem to be a reasonable model for the human situation (28) .
In experiments on anesthetized dogs, Greenbaum et al. (29) reported that inhalation of 2% NO or NO2 resulted in death due to methemoglobinemia, hypoxemia, and pulmonary edema. Using an adult rat model, Stavert and Lehnert (30) found that exposure of up to 1500 pprn of NO for 15 min or 1000 pprn NO for 30 min produced no detectable histopathologic change in the lungs, although rats exposed to 1000 pprn for 30 min became cyanotic and died due to methemoglobinemia. Exposure to 50 pprn NOz for 30 min produced an increase in lung weight, and histologic evidence of lung injury was observed after 30-min exposures to 25 pprn of NO2, but not at lesser exposure concentrations and times. The main concerns with toxicity, therefore, are methemoglobinemia due to NO, and direct pulmonary injury due to NO2. Because NO is oxidized in the presence of oxygen to NO2, it is important to be aware of the time course of this reaction, for which some guidelines have been published (31) . Monitoring for NO2 concentrations close to the subject's airway is also necessary. Methemoglobin levels must also be carefully measured, and it is encouraging that to date in humans there have been no reports of serious methemoglobinemia.
This study which was done in 1-to 24-old neonatal piglets, an animal model which has similar cardiovascular physiology to the neonate, suggests that the human neonate with reversible pulmonary hypertension may well respond to inhaled NO in doses as low as 5 pprn in keeping with the preliminary results of Kinsella el al. (32) . As the full spectrum of toxicity of inhaled NO is not yet determined, it would seem that further clinical trials involving inhaled NO clinically should evaluate doses as low as 5 pprn to avoid accumulation of NO2 and other toxic derivatives of NO. Inhaled NO has now been demonstrated to be beneficial in adults with pulmonary hypertension (33, 34) , adults with adult respiratory distress syndrome (39, children with pulmonary hypertension associated with congenital heart disease (36) , and neonates with persistent pulmonary hypertension of the newborn (32, 37) . No controlled studies, however, have yet demonstrated any effect on outcome, nor on long-term morbidity, and such studies are required before inhaled NO becomes an accepted clinical form of therapy.
